Two Ebola vaccines ready for trial
Two Ebola vaccines in the next two weeks
will be tested on humans
"We expect that the first clinical trials of vaccines will begin in the next two weeks. It will take from 6 months to a year to test the vaccine," Marie Paul Kini said.
She noted that there are currently two vaccines that will be used in clinical trials.
One vaccine (cAd3-ZEBOV) was developed by GlaxoSmithKline in cooperation with the National Institute of Allergy and Infectious Diseases of the USA. It uses an adenoviral vector taken from a chimpanzee with an embedded Ebola virus gene.
The second vaccine (rVSV-ZEBOV) was developed by the Public Health Agency of Canada in Winnipeg. The license for commercial use of the Canadian vaccine belongs to the American company "NewLink Genetics", located in Ames, Iowa. This vaccine is being placed at the disposal of WHO. Its tests will be conducted in the USA, Switzerland, Gabon and Kenya. It is expected that the Canadian vaccines will be delivered to Geneva today, where they will be placed in the refrigerator of the Cantonal Hospital.
250 volunteers aged 18 to 65 will participate in clinical trials of Ebola vaccines.
"There are simply no vaccines that do not lead to side effects at all," the WHO representative said. "But it is impossible to get Ebola as a result of getting vaccinated against this disease."
Preliminary results of the use of the vaccine will be received in December. After the completion of clinical trials, the Ebola vaccine will be used in West African countries, most likely in early 2015. It is not yet clear when these two vaccines will become widely available.
Portal "Eternal youth" http://vechnayamolodost.ru22.10.2014